# IT-11.6: Follow-up Care for Children Prescribed ADHD Medication (ADD)

| **Measure Title** | **IT-11.6 Follow-up care for children prescribed ADHD medication (ADD): initiation phase** |
| --- | --- |
| **Description** | The percentage of children newly prescribed attention deficit / hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed. **Two rates are reported:**  **Rate #1 (Initiation Phase):** The percentage of children 6–12 years of age as of the IPSD with an ambulatory prescription dispensed for ADHD medication, who had one follow-up visit with practitioner with prescribing authority during the 30-day Initiation Phase.  **Rate #2 (Continuation and Maintenance (C&M) Phase)**: The percentage of children 6–12 years of age as of the IPSD with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended. |
| **NQF Number** | 0108 |
| **Measure Steward** | National Committee for Quality Assurance |
| **Link to measure citation** | http://www.qualitymeasures.ahrq.gov/content.aspx?id=47193 |
| **Measure type** | Stand-alone (SA) |
| **Performance and Achievement Type** | Pay for Performance (P4P) - QSMIC   |  |  |  |  | | --- | --- | --- | --- | |  | Baseline | DY4 | DY5 | | Achievement Level Calculations | Baseline below MPL | MPL | MPL + 10%\* (HPL-MPL) | | Baseline above MPL | Baseline + 10%\*(HPL - Baseline) | Baseline + 20%\*(HPL - Baseline) | |
| **Benchmark Description** | |  |  | | --- | --- | | NCQA- 2013 Accreditation Benchmarks and Thresholds | | | HPL (90th Percentile) | Initiation Phase: 52.48%  Continuation Phase: 63.11% | | | MPL (25th Percentile) or 10th if applicable | Initiation Phase: 32.93%  Continuation Phase: 38.36% | | |
| **DSRIP-specific modifications to Measure Steward’s specification** | The Measure Steward’s specification has been modified as follows:   * Changed references to “members” to “patients” * Removed reference to continuous enrollment requirement |
| **Denominator Description** | **Initiation Phase:** Patients 6 years as of March 1 of the year prior to the measurement year to 12 years as of February 28 of the measurement year who were dispensed an attention deficit/hyperactivity disorder (ADHD) medication during the 12-month Intake Period  Continuation Phase: Patients 6 years as of March 1 of the year prior to the measurement year to 12 years as of February 28 of the measurement year who had continuous treatment for at least 210 days out of the 300-day period |
| **Denominator Inclusions** | * Intake Period: The 12-month window starting March 1 of the year prior to the measurement year and ending February 28 of the measurement year. * IPSD: The earliest prescription dispensing date for an ADHD medication where the date is in the Intake Period and there is a Negative Medication History. * Negative Medication History: A period of 120 days (4 months) prior to the IPSD, during which time the member had no ADHD medications dispensed for either new or refill prescriptions. |
| **Denominator Exclusions** | **Initiation Phase:** Exclude patients who had an acute inpatient claim/encounter with a principal diagnosis or Diagnosis Related Group (DRG) code for mental health or substance abuse during the 30 days after the IPSD.  **Continuation Phase:** Exclude patients who had an acute inpatient claim/encounter with a principle diagnosis of mental health substance abuse during the 300 days after the IPSD.  Exclude patients diagnosed with narcolepsy at any point in their medical history. (Optional) |
| **Denominator Size** | Providers must report a minimum of 30 cases per measure during a 12-month measurement period(   * For a measurement period where the denominator size is less than or equal to 75, providers must report on all cases. No sampling is allowed. * For a measurement period where the denominator size is less than or equal to 380 but greater than 75, providers must report on all cases (preferred, particularly for providers using an electronic health record) or a random sample of not less than 76 cases. * For a measurement period where the denominator size is greater than 380, providers must report on all cases (preferred, particularly for providers using an electronic health record) or a random sample of cases that is not less than 20% of all cases; however, providers may cap the total sample size at 300 cases. |
| **Numerator Description** | **Initiation Phase:** Patients from the denominator with one face-to-face outpatient, intensive outpatient or partial hospitalization follow-up visit with a practitioner with prescribing authority, within 30 days after the Index Prescription Start Date  **Continuation Phase:** All patients who meet the following criteria:   * An Initiation Phase visit in the first 30 days * At least two follow-up visits from 31-300 days (10 months) after the IPSD (one of the two visits may be a telephone visit with practitioner). |
| **Numerator Inclusions** | **Initiation Phase:** Do not count a visit on the IPSD visit as the Initiation Phase Visit. |
| **Numerator Exclusions** | There are no additional numerator/denominator inclusions/exclusions specified by the Measure Steward. |
| **Setting** | Ambulatory |
| **Data Source** | Administrative claims |
| **Allowable Denominator Sub-sets** | All denominator subsets are permissible for this outcome |